Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25830736 | 0.89 | KMT2A (0.52) | EPHX2ALDH1A1TSHRFAAHMEN1 | |
| SCHEMBL22790739 | 0.88 | FAAH (0.53) | EPHX2TSHRFAAHMEN1KMT2A | |
| SCHEMBL22906477 | 0.88 | FAAH (0.53) | EPHX2TSHRFAAHMEN1KMT2A | |
| SCHEMBL23559960 | 0.88 | KMT2A (0.50) | EPHX2ALDH1A1TSHRFAAHMEN1 | |
| SCHEMBL25090249 | 0.87 | ALDH1A1 (0.51) | EPHX2ALDH1A1TSHRFAAHHSD17B10 | |
| SCHEMBL23696123 | 0.86 | KDM4E (0.48) | EPHX2ALDH1A1TSHRFAAHSMN1; SMN2 | |
| SCHEMBL22790646 | 0.85 | KDM4E (0.47) | EPHX2ALDH1A1TSHRFAAHSMN1; SMN2 | |
| SCHEMBL21105770 | 0.85 | EPHX2 (0.43) | EPHX2ALDH1A1TSHRFAAHMEN1 | |
| SCHEMBL24508250 | 0.85 | KDM4E (0.47) | EPHX2ALDH1A1TSHRFAAHSMN1; SMN2 | |
| SCHEMBL25591284 | 0.85 | EPHX2 (0.43) | EPHX2ALDH1A1TSHRFAAHKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230065463-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230065463-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | EPHX2 2372/4885ALDH1A1 1358/4885TSHR 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.